Medicare Policy on Bariatric Surgery: Decision Making in the Face of Uncertainty (Sept 2013)
Tunis SR, Messner DA. Medicare policy on bariatric surgery: decision making in the face of uncertainty. J Amer Med Assoc. 2013: doi:10.1001/jama.2013.278849
Preview Here
Since this 2013 article, tirzepatide and semaglutide have been FDA-approved for long-term weight management in adults with obesity (or overweight with a weight-related health problem), which gives some people an option besides surgery. Medicare drug plans still cannot cover these medicines for weight loss alone, but since July 2026 a temporary program, the Medicare GLP-1 Bridge (set to run through 2027), has covered them for some people with obesity or overweight. Drug plans can also cover them for other approved uses, such as tirzepatide for sleep apnea and semaglutide for chronic kidney disease, and both medicines lower blood sugar in adults with type 2 diabetes. Both medications are also approved to lower the risk of heart attack and stroke in people with cardiovascular disease and type 2 diabetes.
Tags:
Sources
- Weight Management Approval: Zepbound label, 2026; Wegovy label, 2026
- Medicare Coverage: Weight Loss Drugs, Medicare.gov, 2026; Medicare GLP-1 Bridge, CMS, 2026; Medicare GLP-1 Bridge Expectations and FAQs, CMS, 2026
- Blood Sugar: Mounjaro label, 2026; Ozempic label, 2026
Browse industry research articles, publications, and other important resources.
-
browse
By Topic
By Disease Area